HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Saved in:

Bibliographic Details
Title:	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Authors:	Nelde A; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Kowalewski DJ; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Immatics Biotechnologies GmbH, Tübingen, Germany., Backert L; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany., Schuster H; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Immatics Biotechnologies GmbH, Tübingen, Germany., Werner JO; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Klein R; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Kohlbacher O; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany.; Quantitative Biology Center, University of Tübingen, Tübingen, Germany.; Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany., Kanz L; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany., Salih HR; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.; Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany., Rammensee HG; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany., Stevanović S; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany., Walz JS; Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
Source:	Oncoimmunology [Oncoimmunology] 2018 Feb 14; Vol. 7 (4), pp. e1316438. Date of Electronic Publication: 2018 Feb 14 (Print Publication: 2018).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2162-4011
DOI:	10.1080/2162402X.2017.1316438